Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.65 |
| ▸ | MAPT | P10636 | 10/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.65 |
| ▸ | TSHR | P16473 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.65 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | MTOR | P42345 | 3/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.65 |
| ▸ | DRD2 | P14416 | 3/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.65 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16281786 | 0.87 | NPC1 (0.52) | TDP1MAPTKDM4EADRB2HSD17B10 | |
| Racepinephrine SCHEMBL21248121 | 0.82 | TDP1 (0.84) | TDP1MAPTKDM4EADRB2HSD17B10 | |
| Epinephrine SCHEMBL21248119 | 0.82 | TDP1 (0.84) | TDP1MAPTKDM4EADRB2HSD17B10 | |
| Racepinephrine SCHEMBL28584300 | 0.82 | TDP1 (0.84) | TDP1MAPTKDM4EADRB2HSD17B10 | |
| SCHEMBL17469083 | 0.81 | NPC1 (0.64) | TDP1MAPTKDM4EADRB2TSHR | |
| SCHEMBL26292967 | 0.81 | ADRB2 (0.61) | TDP1MAPTKDM4EADRB2HSD17B10 | |
| SCHEMBL10931417 | 0.80 | TDP1 (0.56) | TDP1MAPTKDM4EADRB2HSD17B10 | |
| SCHEMBL27338455 | 0.80 | MAPT (0.57) | TDP1MAPTKDM4EADRB2HSD17B10 | |
| SCHEMBL10882684 | 0.79 | MAPT (0.56) | TDP1MAPTKDM4EADRB2HSD17B10 | |
| Racepinephrine SCHEMBL20493843 | 0.79 | KDM4E (1.00) | TDP1MAPTKDM4EADRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818585-B | Separation method for simultaneously preparing five dopamine compounds from aspongopus | 遵义医科大学 | 2023-05-30 | — | — | CN | claimed |
| CN-110818585-B | Separation method for simultaneously preparing five dopamine compounds from aspongopus | 遵义医科大学 | 2023-05-30 | — | — | CN | disclosed |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS INC (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS INC (US) | 2017-08-03 | — | — | US | disclosed |
| EP-3132796-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | Pericor Therapeutics, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9539274-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9539274-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-8993527-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8912332-B2 | Synthesis of trivalent flexible frameworks with ligands comprising catechol units for functionalizing surfaces | JUSTUS-LIEBIG-UNIVERSITAET GIESSEN (DE) | 2014-12-16 | — | — | US | disclosed |
| EP-2428502-B1 | Synthesis of tripodal catechol derivatives with an adamantyl base for functionalising surfaces | Justus Liebig Universität Giessen (DE) | 2014-12-10 | — | — | EP | disclosed |
| EP-2428503-B1 | Synthesis of tripodal catechol derivatives with a flexible base for functionalising surfaces | Justus Liebig Universität Giessen (DE) | 2014-12-10 | — | — | EP | disclosed |
| US-8785641-B2 | Synthesis of tripodal catechol derivatives having an adamantyl basic framework for functionalizing surfaces | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20130245269-A1 | Synthesis of Tripodal Catechol Derivatives Having an Adamantyl Basic Framework for Functionalizing Surfaces | JUSTUS-LIEBIG-UNIVERSITA GIESSEN (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245270-A1 | Synthesis of Trivalent Flexible Frameworks with Ligands Comprising Catechol Units for Functionalizing Surfaces | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2013-09-19 | — | — | US | disclosed |
| WO-2012032084-A1 | SYNTHESIS OF TRIPODAL CATECHOL DERIVATIVES HAVING AN ADAMANTYL BASIC FRAMEWORK FOR FUNCTIONALIZING SURFACES | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032085-A1 | SYNTHESIS OF TRIVALENT FLEXIBLE FRAMEWORKS WITH LIGANDS COMPRISING CATECHOL UNITS FOR FUNCTIONALIZING SURFACES | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2012-03-15 | — | — | WO | disclosed |
| EP-2428503-A1 | Synthesis of tripodal catechol derivatives with a flexible base for functionalising surfaces | Justus-Liebig-Universität Gießen (DE) | 2012-03-14 | — | — | EP | disclosed |
| EP-2428502-A1 | Synthesis of tripodal catechol derivatives with an adamantyl base for functionalising surfaces | Justus-Liebig-Universität Gießen (DE) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | TDP1 1988/4885MAPT 4347/4885KDM4E 2756/4885 |
| US-20130245270-A1 | Synthesis of Trivalent Flexible Frameworks with Ligands Comprising Catechol Units for Functionalizing Surfaces | CHRM3, CHRM5, CHRM4 | TDP1 4517/4885MAPT 4034/4885KDM4E 1565/4885 |
| US-20130245269-A1 | Synthesis of Tripodal Catechol Derivatives Having an Adamantyl Basic Framework for Functionalizing Surfaces | CHRM1, CHRM5, CHRM4 | TDP1 3262/4885MAPT 2680/4885KDM4E 2443/4885 |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | TDP1 1988/4885MAPT 4347/4885KDM4E 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.